Theriva Biologics (TOVX) Return on Invested Capital (2022 - 2023)
Theriva Biologics (TOVX) posted quarterly Return on Invested Capital of 0.04% for Q4 2023, down 3.0% year-over-year from 0.04% in Q4 2022, and down 71.93% quarter-over-quarter from 0.02% in Q3 2023.
Theriva Biologics (TOVX) Return on Invested Capital (2022 - 2023) Analysis & Trends
Theriva Biologics (TOVX) has reported Return on Invested Capital for 2 consecutive years, with 0.04% the latest figure, recorded in Q4 2023.
- In Q4 2023, Return on Invested Capital fell 3.0% year-over-year to 0.04%; the TTM figure through Dec 2023 stood at 0.04% (down 3.0% YoY), while the FY2025 annual figure was 3.22%, up 14.0% from the prior year.
- Return on Invested Capital fell to 0.04% in Q4 2023 per TOVX's latest filing, from 0.02% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.01% in Q4 2022 and bottomed at 0.04% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.17% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -0.04% |
| Sep 30, 2023 | -0.02% |
| Jun 30, 2023 | -0.01% |
| Mar 31, 2023 | -0.01% |
| Dec 31, 2022 | -0.01% |